A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer (NCT06984861) | Clinical Trial Compass
RecruitingPhase 2
A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer
United States74 participantsStarted 2025-05-13
Plain-language summary
The researchers are doing this study is to find out if lower doses (given in fewer treatments over a shorter period of time) of radiation therapy in combination with standard-of-care chemotherapy is an effective treatment for people with Human Papilloma Virus (HPV)-positive throat cancer and works as well as the standard doses of radiation therapy in combination with standard-of-care chemotherapy. The chemotherapy drugs used in combination with radiation therapy in this study include cisplatin, carboplatin, and 5-fluorouracil (5-FU).
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Squamous cell carcinoma of the neck of unknown primary is allowed with excision biopsy of a lymph node (or core biopsy) or consent from the PI or co-PI. Patient must have excisional biopsy or core biopsy done in order to be on protocol.
✓. AST or ALT ≤ 3 x the upper limit of normal Note: Patients who cannot tolerate cisplatin or carboplatin/5FU based on clinical judgment will receive carboplatin and paclitaxel. Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential
Exclusion criteria
✕. Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
✕. Transmural myocardial infarction within the last 6 months
✕. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
✕. Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration